SOURCE: IntelliCell Biosciences, Inc
NEW YORK, NY--(Marketwired - Oct 22, 2013) - IntelliCell BioSciences, Inc. (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVFCs) derived from the blood vessels found in adipose tissue, announced today that it has received notice that its patent application has been filed in Thailand.
IntelliCell's Chairman and CEO, Dr. Steven Victor, stated, "The Company is extremely pleased to announce this patent application for our stem cell extraction technology in Thailand. We believe that this patent application will provide further protection worldwide of Intellicell's regenerative medicine technology. This is our fifth global patent application for this technology, which is now recognized within the United States and Internationally. Going forward, management will continue to increase awareness of the benefits that our proprietary stem cell technology can provide while improving the quality of life of patients with unmet clinical needs. Receiving patent protection is an integral aspect of our business, as it guards against similar practices from our competitors."
This filing represents the fifth international patent application that IntelliCell has procured .This technology is an innovative mechanical method for the separation of stromal vascular fraction cells from blood vessels found in adipose (fat) tissue, without the use of enzymes. Vascular cells derived by IntelliCell's proprietary method are potentially useful in bringing the promise of regenerative medicine to many therapeutic and aesthetic procedures. The Thailand Application number is 1301003638, entitled "Ultrasonic Cavitation Derived Stromal or Mesenchymal Vascular Extracts and Cells Derived Therefrom Obtained from Adipose Tissue and Use Therof."
About IntelliCell Biosciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell Biosciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. One of the revenue streams IntelliCell is pursuing is placing its labs into Hospitals and Ambulatory Surgical Centers. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.